Compile Data Set for Download or QSAR
Report error Found 173 Enz. Inhib. hit(s) with all data for entry = 12348
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696671(6-(1-((1- cyanocyclopropyl)methyl)-1H- pyrazol-4-y...)
Affinity DataIC50: 80nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696673((S)-6-(1-((1- cyanocyclopropyl)methyl)-1H- pyrazol...)
Affinity DataIC50: 620nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696752(N-(2-((2R,4R)-4-hydroxy-2- methylpyrrolidin-1-yl)-...)
Affinity DataIC50: 620nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696797((S)-6-(1-((1- cyanocyclopropyl)methyl)-1H- pyrazol...)
Affinity DataIC50: 650nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696792(6-(1-((1- cyanocyclopropyl)methyl)-1H- pyrazol-4-y...)
Affinity DataIC50: 670nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696755(6-(1-(cyclopropylmethyl)-1H- pyrazol-4-yl)-N-(5-me...)
Affinity DataIC50: 700nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696657(US20240308980, Ex-1.22 | (R) or (S) N-(5-(3- hydro...)
Affinity DataIC50: 770nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696802(N-[3-cyclopropyl-6-[(3R)-3-(1- ethyl)pyrrolidin-1-...)
Affinity DataIC50: 774nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696744((R)-N-(2-(3-(2-hydroxypropan- 2-yl)pyrrolidin-1-yl...)
Affinity DataIC50: 800nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696710((S)-N-(2-cyclopropyl-5-(3- methyl-4-(oxetan-3- yl)...)
Affinity DataIC50: 820nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696651(US20240308980, Ex-1.16 | US20240308980, Ex-1.17 | ...)
Affinity DataIC50: 870nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696723(6-(1-(cyclopropylmethyl)-1H- pyrazol-4-yl)-N-(5-((...)
Affinity DataIC50: 910nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696659(US20240308980, Ex-1.24 | (R, R) or (S, S) or (S, R...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696662(US20240308980, Ex-1.27 | US20240308980, Ex-1.28 | ...)
Affinity DataIC50: 1.02E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696700((S)-N-(2-cyclopropyl-5-(4- methyl-2-oxopyrrolidin-...)
Affinity DataIC50: 1.04E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696645((S)-N-(5-(3-methoxypyrrolidin- 1-yl)-2- (trifluoro...)
Affinity DataIC50: 1.04E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696674(N-(5-(5-azaspiro[2.4]heptan-5- yl)-2-(trifluoromet...)
Affinity DataIC50: 1.08E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696711(N-(2-cyclopropyl-5-((3S,5R)- 3,5-dimethyl-4-(oxeta...)
Affinity DataIC50: 1.09E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696756(6-(1-(cyclopropylmethyl)-1H- pyrazol-4-yl)-N-(2-((...)
Affinity DataIC50: 1.13E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696659(US20240308980, Ex-1.24 | (R, R) or (S, S) or (S, R...)
Affinity DataIC50: 1.20E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696675(6-(1-((1- cyanocyclopropyl)methyl)-1H- pyrazol-4-y...)
Affinity DataIC50: 1.28E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696777((R)-N-(6-(3-(2-hydroxypropan- 2-yl)pyrrolidin-1-yl...)
Affinity DataIC50: 1.36E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696712((S)-N-(2-cyclopropyl-5-(3- methoxypyrrolidin-1- yl...)
Affinity DataIC50: 1.41E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696728(US20240308980, Ex-3.1 | US20240308980, Ex-3.2 | (R...)
Affinity DataIC50: 1.43E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590222(CHEMBL5193374 | US20240308980, Ex-4.18)
Affinity DataIC50: 1.52E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696646(N-(5-(4-(2-hydroxypropan-2- yl)-2-azabicyclo[2.1.1...)
Affinity DataIC50: 1.54E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696759(N-(2-((2S,6R)-2,6- dimethylmorpholino)-5- methylpy...)
Affinity DataIC50: 1.60E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696647(US20240308980, Ex-1.12 | (R) or (S)-N-(5-(3-hydrox...)
Affinity DataIC50: 1.60E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696657(US20240308980, Ex-1.22 | (R) or (S) N-(5-(3- hydro...)
Affinity DataIC50: 1.62E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696719(N-(5-((3R,4S)-3-(2- hydroxypropan-2-yl)-4- methoxy...)
Affinity DataIC50: 1.62E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590221(CHEMBL5180782 | US20240308980, Ex-4.2)
Affinity DataIC50: 1.63E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696751(N-(2-((2R,3S)-3-hydroxy-2- methylazetidin-1-yl)-5-...)
Affinity DataIC50: 1.64E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696764(N-(2-((2S,6R)-2,6- dimethylmorpholino)-5- methylpy...)
Affinity DataIC50: 1.64E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696659(US20240308980, Ex-1.24 | (R, R) or (S, S) or (S, R...)
Affinity DataIC50: 1.65E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696672((S)-6-(1-((1- cyanocyclopropyl)methyl)-1H- pyrazol...)
Affinity DataIC50: 1.73E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696662(US20240308980, Ex-1.27 | US20240308980, Ex-1.28 | ...)
Affinity DataIC50: 1.74E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696650(N-(5-((2R,3S)-3-hydroxy-2- methylpyrrolidin-1-yl)-...)
Affinity DataIC50: 1.78E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696799((R)-N-(6-(3-(2-fluoropropan-2- yl)pyrrolidin-1-yl)...)
Affinity DataIC50: 1.83E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696709((R)-N-(2-cyclopropyl-5-(3- methyl-4-(oxetan-3- yl)...)
Affinity DataIC50: 1.92E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696647(US20240308980, Ex-1.12 | (R) or (S)-N-(5-(3-hydrox...)
Affinity DataIC50: 1.93E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696776(N-(6-((3S,4r,5R)-4-hydroxy- 3,4,5-trimethylpiperid...)
Affinity DataIC50: 2.01E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696699(N-(2-cyclopropyl-5-(2- oxopyrrolidin-1-yl)pyridin-...)
Affinity DataIC50: 2.05E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696653(US20240308980, Ex-1.18 | US20240308980, Ex-1.19 | ...)
Affinity DataIC50: 2.06E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696649(N-(5-((2R,3R)-3-hydroxy-2- methylpyrrolidin-1-yl)-...)
Affinity DataIC50: 2.06E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696762(6-(1-cyclobutyl-1H-pyrazol-4- yl)-N-(5-methyl-2- m...)
Affinity DataIC50: 2.07E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696748(6-(1-methyl-1H-pyrazol-4-yl)-N- (2-(4-(oxetan-3-yl...)
Affinity DataIC50: 2.13E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590218(CHEMBL5190434 | US20240308980, Ex-4.7)
Affinity DataIC50: 2.18E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696745(US20240308980, Ex-4.16 | (R) or (S) N-(2-(3-hydrox...)
Affinity DataIC50: 2.34E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696765(N-(5-methyl-2- morpholinopyridin-4-yl)-6-(1H- pyra...)
Affinity DataIC50: 2.35E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM696798((R)-N-(6-(3-(2-fluoropropan-2- yl)pyrrolidin-1-yl)...)
Affinity DataIC50: 2.57E+3nMAssay Description:Compound potency against LRRK2 kinase activity was determined using LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA) using a...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

Displayed 1 to 50 (of 173 total ) | Next | Last >>
Jump to: